Anna N. A. Tosteson, ScD
Interim Director and Professor of The Dartmouth Institute
Professor of Medicine
Professor of Community and Family Medicine
James J. Carroll 1948 Professor of Oncology
Director, Comparative Effectiveness Research Program, The Dartmouth Institute for Health Policy and Clinical Practice
Associate Director for Population Sciences, Norris Cotton Cancer Center
Associate Director, SYNERGY, Dartmouth's Clinical and Translational Science Institute
The Dartmouth Institute
Community and Family Medicine
Biostatistics (Health Decision Sciences), Harvard University, ScD
Biostatistics, Harvard University, MS
Statistics & Biometry, Cornell University, BS
Norris Cotton Cancer Center
The Dartmouth Institute for Health Policy and Clinical Practice
Dartmouth Medical School
One Medical Center Drive
Lebanon NH 03756
Dr. Anna Tosteson is a decision scientist and health services researcher who studies how the diffusion of innovations in health care are changing health, costs and quality of care. Through study of diverse data sources including registries, clinical and epidemiological studies, and administrative claims data, she seeks insights into the long-term clinical and economic effects of alternative approaches to health care delivery with a focus on cancer screening, musculoskeletal disease, and women’s health.
Promoting follow-up of abnormal cancer screening tests using population-based systems to support stepped care multilevel intervention. (NCI: U01CA225451 )
Risk-based breast cancer screening and surveillance in community practice. (NCI, P01CA154292)
PH 119/121; QBS 140 Decision and Cost-Effectiveness Analysis
Prioritizing Measures That Matter Within a Person-Centered Oncology Learning Health System.
Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density.
Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer.
Natural Language Processing to Identify Abnormal Breast, Lung, and Cervical Cancer Screening Test Results from Unstructured Reports to Support Timely Follow-up.
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
Factors Influencing Telemedicine Use at a Northern New England Cancer Center During the COVID-19 Pandemic.
Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification.
Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography.
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.